Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Fundraising

Omni HR

Omni HR Raises $7.4M in Series A

SingaporeDecember 13, 20242 min read
Employees
60+

Omni HR Raises $7.4M in Series A


Omni HR has successfully raised $7.4M in a Series A at a $40M valuation led by Picus Capital, Vulcan Capital.


Company Overview


Omni HR is a HR Tech company headquartered in Singapore, founded in 2019 with 60+ employees.


Cloud-based HR management platform for payroll and workforce management


Fundraising Details


  • Amount Raised: $7.4M
  • Round Type: Series A
  • Valuation: $40M
  • Date: 2024-12-13
  • Investors: Picus Capital, Vulcan Capital

About Omni HR


Cloud-based HR management platform for payroll and workforce management The company is positioned in the HR Tech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Singapore
  • Founded: 2019
  • Team Size: 60+
  • Industry: HR Tech

What This Means


This funding round demonstrates strong investor confidence in Omni HR's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HR Tech sector continues to attract significant investment as companies innovate to meet evolving market demands. Omni HR's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $40M valuation marks an important milestone for Omni HR, positioning the company among notable players in the HR Tech industry.


Looking Ahead


With this new capital, Omni HR is well-positioned to execute on its growth strategy and continue building innovative solutions in the HR Tech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-12-13. For more information about Omni HR, visit their headquarters at Singapore.

Company Info

Headquarters
Singapore
Founded
2019
Team Size
60+

Topics

Fundraising(2912)HR Tech(290)Series AOmni HR

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free